Background: Lung cancer patients are at increased risk for vascular events possibly due to cancer induced hypercoagulation. Aim: The purpose of this study was to evaluate risk factors associated with the mortality from vascular thromboembolic events in patients diagnosed with non-small cell lung cancer (NSCLC). Design: Retrospective population-based analysis. Methods: We used Surveillance, Epidemiology and End Results Program for 2004-13 and evaluated 199 337 patients with NSCLC. Univariate and multivariate subdistribution hazard regression models were used to identify potential risk factors for mortality from vascular thromboembolic events. Stratification analysis against clinical stage was performed to determine if the severity of the disease influenced the identified associations. Results: Multivariate Cox regression analysis demonstrated that increased risk of mortality due to vascular thromboembolic events was associated with age, black race, non-adenocarcinoma histology, surgical treatment alone (all, P < 0.001) and north central region of SEER registry (P ¼ 0.003). Female gender (P < 0.001), Asian or Pacific Islander race (P ¼ 0.001), multiple co-existing primary cancers and late cancer stages (both, P < 0.001) were associated with significantly lower risk of mortality due to vascular thromboembolic events. The significant predictors of mortality from the vascular thromboembolic event were dependent on the stages of the disease. Conclusions: Risk factors associated with mortality from the vascular thromboembolic events in NSCLC patients identified in this study can promote awareness and may help to identify groups of patients that can benefit from anti-thrombotic prophylaxis measures.
Introduction
Cancer is one of the primary causes of death worldwide, with lung cancer being the leading cause of cancer mortality among both genders. 1 Lung cancer accounts for 25% of all cancer deaths, which is more than of colon, breast and prostate cancers combined. 1 Approximately 95% of all lung cancers are classified as either small cell lung cancer (SCLC) or non-small cell lung cancer (NSCLC), with NSCLC diagnosed in up to 85% of cases. Other lung cancer subtypes comprise 5% of malignancies arising in the lung. 2 This classification is essential for staging, treatment and prognosis. It was shown that incidence of stroke and thrombotic events is higher in patients with cancer in general and lung cancer in particular compared with general population, suggesting that cancer itself may contribute to the development of vascular events. Interestingly, it was shown that conventional risk factors, such as hypertension and hyperlipidemia are significantly less prevalent in stroke patients with cancer. 3 Proposed mechanisms of cancer-associated stroke and other thrombotic events include cancer induced hypercoagulability as well as complications of anti-tumor treatments. 3, 4 Few studies investigated the relationship between cancer and stroke or vascular thromboembolic events in NSCLC patients. In the population-based cohort study, Chen et al. 5 found that patients with lung cancer are at increased risk of developing stroke compared with subjects without cancer. Interestingly, elevated risk of stroke decreased over time, declining beyond 1 year after the diagnosis of lung cancer for men and 2 years after the diagnosis for women. 5 Similarly, Navi et al. 6 in a SEER-based study aimed to assess the risk of stroke in newly diagnosed cancer patients demonstrated that cancer incidence was associated with an increased short-term risk of stroke. The highest risk of stroke was associated with lung, pancreatic and colorectal cancers. Kato et al. demonstrated that the incidence of cardiac infarction is elevated in advanced or postoperative recurrent NSCLC, and is particularly high in patients with brain metastasis. 7 Besides, lung cancer patients were
shown to be at increased risk of developing pulmonary embolism compared with cancer-free controls. 8 The occurrence of stroke and other vascular thromboembolic events in cancer patients has a dramatic effect on outcome and leads to extremely poor prognosis. Consequently, the accurate prognosis of vascular complications in cancer patients can lead to timely prophylactic measures in at-risk patients and ultimately improve survival.
The aim or our study was to determine the risk factors associated with the mortality resulting from vascular thromboembolic diseases, such as stroke, cerebrovascular disease, cardiovascular disease and others among NSCLC patients using nationwide population-based data available from SEER database.
Materials and methods

Data source
The study involved a retrospective evaluation of medical records from Surveillance, Epidemiology and End Results (SEER) Program (www.seer.cancer.gov), Research Data (1973 Data ( -2013 , National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2016, based on the November 2015 submission. SEER is a populationbased registry sponsored by the National Cancer Institute. It collects data on cancer incidence and survival from 17 geographic areas in the US, including 28% of the US population. 9 SEER contains de-identified data, and analysis of the data does not require IRB approval or informed consent from patients. We have got permission to access the research data file in the SEER program by National Cancer Institute, USA with the reference number 15306-Nov2015-July 2016.
Study population
New-onset primary NSCLC diagnoses that occurred between 1 January 2004 and 31 December 2013, were identified through SEER cancer registries using ICD for Oncology third edition codes C34.0-34.9. Respective histologic codes included ICD-O-3: 8140-8147/3, 8070-8078/3 and 8012-8014/3. Cancer registries were used to obtain information on cancer stage at diagnosis which was categorized into early stage (I-IIIA) or late stage (IIIB-IV).
Study variables
The primary endpoint of the present study was overall survival (OS). OS was calculated from the day of diagnosis to the date of death from any cause, which was indicated as 'vital status' in the SEER database. The secondary endpoint was the cause of death, which was categorized into the cancer-related cause of death and non-cancer-related causes of death. The cancerrelated cause of death included deaths from lung cancer and cancer of surrounding organs, while non-cancer-related causes of death included deaths from cerebrovascular disease, cardiovascular disease and other vascular disorders.
The variables obtained for each case included patient demographics (age at diagnosis, sex, race/ethnicity, a region of SEER registry), clinical characteristics of the malignancy (histology, AJCC staging system), the status of co-existing primary cancer and treatment modalities (surgery, radiotherapy).
Statistical analysis
Categorical data were represented by a number (n) and percentage (%) and continuous variables were represented as the mean and standard deviation (SD).
The aim of the present study was to determine the mortality from vascular thromboembolic events in NSCLC patients; however, competitive risks often arise when the occurrence of one type of event prevents the occurrence of other types of events. 10 In this case, mortality from lung and surrounding organs cancer competes with vascular disease-triggered mortality. To account for the effect of competing risk, the subdistribution hazard regression model proposed by Fine and Gray 11 was used.
Univariate and multivariate subdistribution hazard regression models were used to identify potential risk factors for mortality from vascular thromboembolic events. Stratification analysis against clinical stage was performed to determine if the severity of the disease influenced the identified associations. The significance level was set to 0.05. All analyses were performed with SAS statistical software (version 9.4, SAS Inc., NC, USA).
Results
Characteristics of study subject Table 1 ).
The incidence of mortality from vascular thromboembolic events
On the basis of the cumulative incidence estimates, patients with late stages of lung cancer had a lower risk of death from vascular thromboembolic events than those with early stages (P < 0.001; Figure 1 ). The 1-year, 3-year and 5-year-rates of mortality from vascular thromboembolic events for patients with early stages of the lung cancer were 2.5%, 3.9% and 4.8%, respectively. For patients with late stages of cancer, the 1-year, 3-year and 5-year rates of mortality from vascular events were 1.3%, 2.1% and 2.6%, respectively. (Table 2) .
It is possible that the risk of mortality from vascular thromboembolic events depends on the severity of the disease characterized by the operability of tumor and stage of cancer. To address this possibility, we performed stratification analysis against clinical stage.
For patients with early stages of NSCLC, the risk of mortality due to vascular diseases was significantly increased with age (aHR ¼ 1.05, 95% CI ¼ 1.04-1.05, P < 0.001), black race (aHR ¼ 1. Table 3 ).
Discussion
Understanding risk and susceptibility factors associated with the development of vascular thromboembolic complications in NSCLC patients can help guide clinical decision-making regarding appropriate anti-thrombotic prophylaxis measures. To address this question, we aimed to estimate the incidence of mortality from the vascular thromboembolic event in lung cancer patients and determine risk factors associated with this mortality. We found that mortality due to vascular thromboembolic events was 3.2% of the study population. Vascular disease-triggered mortality was higher in patients with early stages of lung cancer (4.4%), compared with patients with late stages of the disease (2.3%). It is possible that, due to better clinical outcomes, patients with early stages of lung cancer have longer time when vascular events can occur.
Recent studies investigated the prevalence of thromboembolic events. Prophylaxis of Thromboembolism during Chemotherapy trial 12 reported that 3.9% of lung cancer patients developed thromboembolic events. This study also emphasized that the rate of thromboembolic events was the highest in patients with lung (8.8%) and pancreas (5.9%) cancers, highlighting the necessity for future studies on these high-risk groups of cancer patients. We found that age, black race, non-adenocarcinoma histology, surgical treatment alone and north central region of SEER registry were independent risk factors associated with mortality from vascular thromboembolic events. Female gender, Asian or Pacific Islander race, co-existing multiple primary cancers and late stage of disease (stage IIIB-IV) were factors associated with reduced risk of mortality from vascular thromboembolic events.
Our results also demonstrate that the effects of gender, race/ ethnicity and surgical treatment may be modified by disease progression. The risk of death from vascular thromboembolic events was reduced by 29% in females with early stages of NSCLC (aHR ¼ 0.71), and only by 14% in females with late stages of the disease (aHR ¼ 0.86). Black patients with late stages of lung cancer were at higher risk of mortality from vascular thromboembolic events than those with an early stage of the disease (aHR ¼ 1.39 and aHR ¼ 1.18, respectively). Finally, the surgical treatment alone was a stronger risk factor for mortality from vascular thromboembolic events in patients with latestage NSCLC (aHR ¼ 1.54) compared with the early-stage disease (aHR ¼ 1.20).
In addition to the staging of cancer, cancer treatment modalities may also contribute to the incidence and mortality from vascular thromboembolic events. It was previously shown that patients undergoing surgery for cancer treatment are at increased risk of post-operative deep vein thrombosis. 13 In addition, a fatal pulmonary embolism is 3-fold more common in cancer patients compared with non-cancer patients undergoing the same surgical procedure. 14 Extensive surgery in lung cancer patients, which is likely to take place in patients with the latestage disease was shown to be associated with increased incidence of venous thromboembolism. 15 We found that surgical treatment alone was associated with increased mortality from vascular thromboembolic events, while radiotherapy alone reduced this risk. Interestingly, combination of radiotherapy and complete resection was associated with reduced risk of mortality from thromboembolic events to about the same level as with radiotherapy treatment alone (aHR ¼ 0.75, 95% CI ¼ 0.71, 0.78, P < 0.001 for radiotherapy only and aHR ¼ 0.82, 95% CI ¼ 0.70, 0.96, P ¼ 0.013 for combination of radiotherapy and complete resection). One can speculate that radiotherapy may have a dominant effect on the risk of thromboembolic event when combined with some surgical treatment modalities. Chemotherapy and targeted therapy treatments were also reported to increase the rate of thromboembolic events. [16] [17] [18] Since the information and details of chemotherapy are underreported in SEER database, we were unable to analyze this risk factor in this study.
Previous studies investigated the dependence of thromboembolic events on the histology of lung cancer and found that adenocarcinomas are associated with increased risk of clotting disorders and stroke compared with squamous-cell carcinomas. 19, 20 Mucin-producing adenocarcinomas were found to be associated with the highest risk of vascular thromboembolic events; possibly due to secretion of procoagulant factors induced by mucus. 21 In odds with these reported data, we found that non-adenocarcinoma histology is an independent risk factor associated with mortality from vascular thromboembolic events.
Apart from cancer-related factors, patient-related factors play a role in the development and mortality of thromboembolic events in lung cancer. Several traditional risk factors mortality from vascular thromboembolic events is often present in patients with different types of cancer. These risk factors include older age, prolonged immobility, prior history of venous thrombosis and other comorbidities. We also found that race and ethnicity is a prognostic factor associated with mortality from vascular thromboembolic events in lung cancer patients. Our results agree with published studies focused on other types of cancer. For instance, Khorana et al. also showed that black cancer patients had significantly increased risk of venous thromboembolism (odds ratio [OR] of 1.18; 95% CI, 1.15-1.22), while cancer patients with Asian ethnicity had a decreased risk of venous thrombosis (OR 0.7; 95% CI: 0.7-0.8) when compared with whites/Caucasians. It is thought that elevated levels of Factor VIII may be responsible for increased rate of venous thromboembolism in the black population, 22 however, it is not known if it is the case for cancer patients. Our results also parallel observations from another study which demonstrated that the risk of venous thrombosis was significantly reduced in colorectal cancer patients of Asian/Pacific Islander origin (HR 0.4; 95% CI: 0.3-0.4) compared with white patients. 23 The observed phenomenon is likely due to the generally lower risk of venous thrombosis in Asians/Pacific Islanders. 24, 25 It is possible that genetic differences contribute to observed differences in susceptibilities; however, more studies are required to address this question.
The impact of gender on thromboembolic events in lung cancer patients is not clear. We found that female gender is associated with significantly lower risk of mortality due to vascular thromboembolic events in NSCLC patients. It is possible that hormonal or lifestyle differences are responsible for the observed results. Krö ger et al. did not find gender-specific differences in the risk of venous thromboembolic events in cancer patients. 26 Khorana et al. and Hall et al. observed an increased risk of venous thromboembolic events in females. 27, 28 Clearly, additional studies are needed to confirm our conclusions. The strengths and limitations of this study arise from the SEER database as a data source. This database is large and comprehensive, includes information on various tumor characteristics, follow-ups for vital status and cause of death. Data are collected primarily from an institutional source, and findings are more applicable to the general population with limited selection bias. Also, a quality control program is conducted each year by the National Cancer Institute to evaluate the quality and completeness of the SEER data. On the other hand, the information and details of chemotherapy and radiotherapy are underreported, and lack of this information may be a potential confounding factor in our results. Besides, SEER lacks randomization and information on potential comorbidities.
Regardless of the above-mentioned limitations, we believe that our results provide useful information that can be used for identification of a subgroup of NSCLC patients which are at high risk for the development and death from the thrombotic events. This information can be used to identify candidates for primary thromboprophylaxis and can help guide clinical decisionmaking regarding appropriate patient care.
